With New Agreement, DermTech Melanoma Test Available Through DermatologistOnCall

The DermTech Melanoma Test is now available through DermatologistOnCall’s telemedicine platform. 

The DermTech Melanoma Test is a non-invasive test used to painlessly collect cellular material from the surface of a patient’s mole via the DermTech Smart Sticker™. A patient sample can be collected at home under virtual supervision by a trained DermatologistOnCall clinician. The sample is sent to the DermTech Gene Lab where it is tested for genomic markers linked to melanoma. Any diagnosis or further treatment recommendation are based on the individual’s test results and the reviewing dermatologist’s medical judgment. Patients will be referred to a local physician for additional treatment as appropriate. 

Evaluation by a DermatologistOnCall Dermatologist and subsequent DermTech Melanoma Test results take an average of 10 days. A visit with DermatologistOnCall costs just $95 or less depending on insurance coverage, and the DermTech Melanoma Test is covered by Medicare and certain commercial insurance carriers.

“Our mission is to democratize access to high-quality dermatology care,” says John Dobak, MD, CEO of DermTech. “We believe no one should have to die from melanoma and relationships with great innovators like DermatologistOnCall allow for increased physician and patient access to our test, helping to ensure that early melanoma detection is simple and attainable.”

“We believe this relationship will play a significant role in combatting preventable melanoma deaths,” says Douglas Holmes, CEO of DermatologistOnCall. “More than 20 million Americans will have access to DermatologistOnCall as a covered benefit on January 1, 2022. Our direct-to-patient platform is open in all 50 states and the District of Columbia. Every American can receive comprehensive dermatology care through our platform—including affordable, accessible, and precise genomic melanoma testing—whenever and wherever it is needed.”